AJ: You lose your autonomy a little bit on the second record. Not only are you trying to make sure you don’t come out with a ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

The much-awaited second season of Laughter Chefs is all set to premiere on January 25, bringing back its unique blend of ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Aly Shockey led with 14 points while plenty of other Indians contributed heavily in the scoring department on Friday.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health outcomes, such as dementia and stroke, a new analysis published in Nature ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...